Is IL-23 Better than IL-17 Inhibition in Psoriasis? Save
Data presented at the recent American Academy of Dermatology meeting suggests that interleukin (IL)-23 inhibition with risankizumab was more effective than the IL-17 inhibition (secukinumab) based on a 52 week randomized head-to-head trial in moderate to severe psoriasis patients.
The IMMerge study was a Phase 3b, 327 patient, head-to-head, 52 week trial comparing skin outcomes in psoriasis patients randomized to receive either risankizumab (RIZ) or secukinumab (SEC).
At week 52, the PASI 100 rates were 66% for RIZ and 40% for SEC (p<0.001).
The PASI 90 at week 16 was the primary endpoint and also favored RIZ over SEC (74% vs 66%) and remained positive out to week 52 (PASI 90 87% vs 57%; p<0.001).
There were no new safety signals observed in the study and were comparable between agents.
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
The author has received compensation as an advisor or consultant on this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.